Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
Catalogo dei prodotti della ricerca
Objective: To compare the disease course in patients with mild Guillain-Barré syndrome (GBS) who were treated with intravenous immunoglobulin (IVIg) or supportive care only. Methods: We selected patients from the prospective observational International GBS Outcome Study (IGOS) who were able to walk independently at study entry (mild GBS), treated with one IVIg course or supportive care. The primary endpoint was the GBS disability score four weeks after study entry, assessed by multivariable ordinal regression analysis. Results: Of 188 eligible patients, 148 (79%) were treated with IVIg and 40 (21%) with supportive care. The IVIg group was more disabled at baseline. IVIg treatment was not associated with lower GBS disability scores at 4 weeks (adjusted OR (aOR) 1.62, 95% CI 0.63 to 4.13). Nearly all secondary endpoints showed no benefit from IVIg, although the time to regain full muscle strength was shorter (28 vs 56 days, p=0.03) and reported pain at 26 weeks was lower (n=26/121, 22% vs n=12/30, 40%, p=0.04) in the IVIg treated patients. In the subanalysis with persistent mild GBS in the first 2 weeks, the aOR for a lower GBS disability score at 4 weeks was 2.32 (95% CI 0.76 to 7.13). At 1 year, 40% of all patients had residual symptoms. Conclusion: In patients with mild GBS, one course of IVIg did not improve the overall disease course. The certainty of this conclusion is limited by confounding factors, selection bias and wide confidence limits. Residual symptoms were often present after one year, indicating the need for better treatments in mild GBS.
Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome. An international observational study / C., Verboon; T., Harbo; D. R., Cornblath; R. A. C., Hughes; P. A., Van Doorn; M. P., Lunn; K. C., Gorson; F., Barroso; S., Kuwabara; G., Galassi; H. C., Lehmann; S., Kusunoki; R. C., Reisin; D., Binda; G., Cavaletti; Andersen, Jacobs B. C. H.; Md, ; (Aarhus University Hospital, Phd; Denmark), Aarhus; Attarian, S.; Md, ; (CHU Timone, Phd; France), Marseille; Badrising, U. A.; Md, ; (Leiden University Medical Centre, Phd; Leiden, ; Netherlands), The; Bateman, K.; Md, ; (Groote Schuur Hospital, Phd; Town, Cape; South-Africa), ; Benedetti, L.; Md, ; (Ospedale Sant’ Andrea La Spezia, Phd; Spezia, La; Italy), ; van den Berg, B.; (Franciscus Gasthuis, Md; Rotterdam, ; Netherlands), The; Van den Bergh, P.; Md, ; Luc, PhD (University Clinic St.; Belgium), Leuven; Bertorini, T. E.; (The University of Tennessee Health Science Center (UTHSC), Md; USA), Memphis; Bhavaraju-Sanka, R.; (University Hospital/ University of Texas Health Science Center, Md; Antonio Texas, San; USA), ; Bianco (Milan University, M.; Clinicala and Research Institute Milan, Humanitas; Italy), ; Briani, C.; (University of Padova, Md; Italy), Padova; Bürmann, J.; (Universitätsklinikum des Saarlandes, Md; Germany), Homburg; Casasnovas, C.; Md, ; Ciberer, PhD (Bellvitge University Hospital - IDIBELL Neurometabolic Diseases Group.; Spain), Barcelona; Chao, C. C.; Md, ; (National Taiwan University Hospital, Phd; Taiwan), Taipei; Chavada, G.; Md, ; (Glasgow University, Phd; UK), Glasgow; Claeys, K. G.; Md, ; University Hospitals Leuven, PhD (1.; Belgium, Leuven; KU Leuven, 2.; Belgium), Leuven; Cosgrove, J. S.; (Leeds General Infirmary, Md; UK), Leeds; Dalakas, M. C.; Thomas Jefferson University, MD (1.; Usa, Philadelphia; National and Kapodistrian University of Athens, 2.; Greece), Athens; Davidson, A.; (University of Glasgow, Md; UK), Glasgow; van Dijk, G. W.; (Canisius Wilhelmina Hospital, Md; Nijmegen, ; Netherlands), The; Dardiotis, E.; (University of Thessaly, Md; of Larissa, Hospital; Greece), Larissa; Derejko, M.; (Odense University Hospital, Md; Denmark), Odense; Dimachkie, M. M.; (University of Kansas Medical Center, Md; City, Kansas; USA), ; Dornonville de la Cour, C.; (National Hospital Copenhagen, Md; Denmark), Copenhagen; Echaniz-Laguna, A.; (Bicêtre University Hospital, Md; France), Paris; Eftimov, F.; Md, ; (Amsterdam University Medical Centre, Phd; Amsterdam, ; Netherlands), The; Faber, C. G.; Md, ; (Maastricht University Medical Centre, Phd; Maastricht, ; Netherlands), The; Fazio, R.; (Scientific Institute San Raffaele, Md; Italy), Milan; Fulgenzi, J. Fehmi (University of Oxford E. A.; (Hospital Cesar Milstein Buenos Aires, Md; Aires, Buenos; Argentina), ; García-Sobrino, T.; (Hospital Clínico de Santiago, Md; de Compostela (A Coruña), Santiago; Spain), ; Gijsbers, C. J.; (Vlietland Hospital, Md; Schiedam, ; Netherlands), The; Granit, V.; (Montefiore Medical, Md; Center, ; York, New; USA), ; Grisanti, S.; (Ospedale Sant’ Andrea La Spezia, Md; Spezia, La; Italy), ; Gutiérrez-Gutiérrez, G.; (Hospital Universitario Infanta Sofia, Md; Sebastian, San; Spain), ; Holbech, J. V.; Md, ; (Odense University Hospital, Phd; Denmark), Odense; Holt, J. K. L.; Phd, ; (The Walton Centre, Frcp; UK), Liverpool; Homedes, C.; Ciberer, MD (Bellvitge University Hospital - IDIBELL Neurometabolic Diseases Group.; Spain), Barcelona; Islam, B.; Md, ; (International Centre for Diarrhoeal Disease Research, Phd; (icddr, Bangladesh; Dhaka, b); Bangladesh), ; Islam, Z.; Md, ; (International Centre for Diarrhoeal Disease Research, Phd; (icddr, Bangladesh; Dhaka, b); Bangladesh), ; Jahan, I.; candidate (International Centre for Diarrhoeal Disease Research, Phd; (icddr, Bangladesh; Dhaka, b); Bangladesh), ; Jericó Pascual, I.; Md, ; (Complejo Hospitalario de Navarra, Phd; Spain), Pamplona; Karafiath, S.; (University of Utah School of Medicine, Md; Lake City, Salt; USA), ; Kerkhoff, H.; Md, ; (Albert Schweitzer Hospital, Phd; Dordrecht, ; Netherlands), The; Kimpinski, K.; (University Hospital, Md; London-Ontario, Lhsc; Canada), ; Kohler, A.; (Instituto de Investigaciones Neurológicas Raúl Carrea, Md; Fleni, ; Aires, Buenos; Argentina), ; Kolb, N.; (University of Vermont, Md; Vt, Burlington; USA), ; Kuitwaard, K.; Md, ; Albert Schweitzer Hospital, PhD (1.; Dordrecht, ; Erasmus MC, 2.; Rotterdam, ; Netherlands), The; Kuwahara, M.; Md, ; (Kindai University, Phd; Japan), Osaka; Ladha, S. S.; (Barrow Neurology Clinics, Md; Arizona, Phoenix; USA), ; Lee Pan, E.; (Groote Schuur Hospital, Mbchb; Town, Cape; South-Africa), ; Marfia, G. A.; (Neurological Clinic, Md; Tor Vergata, Policlinico; Italy), Rome; Magot, A.; (Reference Centre for NMD, Md; University Hospital, Nantes; France), ; Márquez Infante, C.; (Hospital Universitario Virgen del Rocio, Md; Spain), Seville; Martín-Aguilar, L.; i Sant Pau, MD (Hospital de la Santa Creu; Autònoma de Barcelona, Universitat; Spain), Barcelona; Martinez Hernandez, E.; i Sunyer (IDIBAPS), MD (Institut d’Investigacions Biomèdiques August Pi; Clinic, Hospital; Spain), Barcelona; Mataluni, G.; Md, ; (Neurological Clinic, Phd; Tor Vergata, Policlinico; Italy), Rome; Meekins, G.; (University of Minnesota, Md; USA), ; Miller, J. A. L.; Md, ; (Royal Victoria Infirmary, Phd; UK), Newcastle; Monges, M. S.; Garrahan, MD (Hospital de Pediatría J. P.; Aires, Buenos; Argentina), ; Nobile Orazio, E.; Md, ; (Milan University, Phd; Clinicala and Research Institute Milan, Humanitas; Italy), ; Pardal, A.; (Hospital Britanico, Md; Aires, Buenos; Argentina), ; Pardo Fernandez (Hospital Clínico de Santiago, J.; de Compostela (A Coruña), Santiago; Spain), ; Péréon, Y.; Md, ; (Reference Centre for NMD, Phd; University Hospital, Nantes; France), ; Pulley, M.; (University of Florida, Md; USA), Jacksonville; Querol Gutierrez, L.; Md, ; i Sant Pau, PhD (Hospital de la Santa Creu; Autònoma de Barcelona, Universitat; Spain), Barcelona; Reddel, S. W.; Md, ; (Concord Repatriation General Hospital, Phd; Australia), Sydney; van der Ree, T.; (Westfriesgasthuis, Md; Hoorn, ; Netherlands), The; Rinaldi, S.; Mbchb, ; Samijn, PhD (University of Oxford J. P. A.; (Maasstad Hospital, Md; Rotterdam, ; Netherlands), The; Samukawa, M.; Md, ; (Kindai University, Phd; Japan), Osaka; Santoro, L.; Md, ; (University Federico II, Phd; Italy), Napels; Savransky, A.; Md, ; Garrahan, PhD (Hospital de Pediatría J. P.; Aires, Buenos; Argentina), ; Schwindling, L.; (Universitätsklinikum des Saarlandes, Md; Germany), Homburg; Sedano Tous, M. J.; (Hospital Universitario Marques de Valdecilla, Md; Cantabria, Santander; Spain), ; Sekiguchi, Y.; Md, ; (Chiba University, Phd; Japan), Chiba; Shahrizaila, N.; (Neurology Unit, Md; of Medicine, Department; of Medicine, Faculty; of Malaya, University; Malaya), ; Silvestri, N. J.; Sindrup, MD (Buffalo Jacobs School of Medicine S.; Md, ; (Odense University Hospital, Phd; Denmark), Odense; Sommer, C. L.; (Universitätsklinikum Würzburg, Md; Germany), Würzburg; Spyropoulos (Royal Victoria Infirmary, A.; UK), Newcastle; Stein, B.; Joseph’s Regional Medical Center, MD (St.; USA), Paterson; Tan, C. Y.; (Neurology Unit, Mrcp; of Medicine, Department; of Medicine, Faculty; of Malaya, University; Malaya), ; Tankisi, H.; Md, ; (Aarhus University Hospital, Phd; Denmark), Aarhus; Vermeij, F.; (Franciscus Gasthuis, Md; Rotterdam, ; Netherlands), The; Vytopil, M. V.; Md, ; Wirtz, PhD (Tufts University School of Medicine Lahey Hospital P. W.; Md, ; (HagaZiekenhuis, Phd; Hague, The; Netherlands), The; Waheed, W.; (University of Vermont Medical Center, Md; Burlington, ; Addington, USA). Other collaborators were:J. M.; (University of Virginia, Md; USA), Charlottesville; Ajroud-Driss, S.; (Northwestern University Feinberg, Md; USA), Chicago; Antonini, G.; (Mental Health and Sensory Organs (NESMOS), Md; University, Sapienza; Hospital, Sant’Andrea; Italy), Rome; Bella, I. R.; (University of Mass Medical School, Md; USA), Worcester; Brannagan, T. H.; (Columbia University, Md; York City, New; USA), ; Bunschoten, C.; Md, ; candidate (Erasmus University Medical Centre, Phd; Rotterdam, ; Netherlands), The; Busby, M.; (Leeds General Infirmary, Md; UK), Bradford; Butterworth, S.; (Pinderfields Hospital, Md; UK), Wakefield; Conti, M. E.; (University Hospital Clinicas, Md; Aires, Buenos; Argentina), ; Chen, S.; Md, ; (Rutgers, Phd; Wood Johnson University Hospital, Robert; Brunswick, New; USA), ; Doets, A.; Md, ; candidate (Erasmus University Medical Centre, Phd; Rotterdam, ; Netherlands), The; Feasby, T. E.; (University of Calgary, Md; Canada), Calgary; Fokke, C.; (Gelre Hospital, Md; and Apeldoorn, Zutphen; Netherlands), The; Fujioka, T.; (Toho University Medical Center, Md; Japan), Tokyo; Garssen, M. P. J.; Md, ; (Jeroen Bosch Hospital, Phd; Hertogenbosch, ’S; Netherlands), The; Gilchrist, J. M.; (Soulthern Illinois University School of Medicine, Md; USA), Springfield; Gilhuis, J.; Md, ; (Reinier de Graaf Gasthuis, Phd; Delft, ; Netherlands), The; Goldstein, J. M.; (Yale University School of Medicine, Md; Haven, New; USA), ; Goyal, N. A.; (University of California, Md; USA), Irvine; Hadden, R. D. M.; Md, ; (King’s College Hospital, Phd; UK), London; Hsieh, S. T.; Md, ; (National Taiwan University Hospital, Phd; Taiwan), Taipei; Htut, M.; George’s Hospital, MD (St.; UK), London; Illa, I.; Md, ; i Sant Pau, PhD (Hospital de la Santa Creu; Autònoma de Barcelona, Universitat; Spain), Barcelona; Jellema, K.; Md, ; (Haaglanden Medisch Centrum, Phd; Hague, The; Netherlands), The; Kaida, K.; Md, ; (National Defense Medical College, Phd; Japan), Saitama; Katzberg, H. D.; (University of Toronto, Md; Canada), Toronto; Kiers, L.; (University of Melbourne, Md; Melbourne Hospital, Royal; Australia), Parkville; Kokubun, N.; (Dokkyo Medical University, Md; Japan), Tochigi; van Koningsveld, R.; Md, ; (Elkerliek Hospital, Phd; and Deurne, Helmond; Netherlands), The; van der Kooi, A. J.; Md, ; (Amsterdam University Medical Centre, Phd; Amsterdam, ; Netherlands), The; Kwan, J. Y.; (University of Maryland School of Medicine, Md; USA), Baltimore; Landschoff Lassen, L.; (Glostrup Hospital, Md; Denmark), Glostrup; Lawson, V.; (Wexner Medical Center at The Ohio State University, Md; USA), Columbus; Leonhard, S. E.; Md, ; candidate (Erasmus University Medical Centre, Phd; Rotterdam, ; Netherlands), The; Mandarakas, M.; Md, ; (Erasmus University Medical Centre, Phd; Rotterdam, ; Netherlands), The; Manji, H.; Md, ; (Ipswich Hospital, Frcp; UK), Ipswich; Mattiazzi, M. G.; (Hospital Militar Central, Md; Aires, Buenos; Argentina), ; Mcdermott, C. J.; (Royal Hallamshire Hospital, Md; Clinical, Nihr; UK), Sheffield; Mohammad, Q. D.; Md, ; (National Institute of Neurosciences and Hospital, Phd; Bangladesh), Dhaka; Morís de la Tassa, G.; (Hospital UniversitarioCentral de Asturias, Md; Spain), Asturias; Nascimbene, C.; Md, ; (Luigi Sacco Hospital, Phd; Italy), Milan; Niks, E. H.; Md, ; (Leiden University Medical Centre, Phd; Leiden, ; Netherlands), The; Nowak, R. J.; (Yale University School of Medicine, Md; Haven, New; USA), ; Osei-Bonsu, M.; Md, ; (James Cook University Hospital, Phd; UK), Middlesbrough; Pascuzzi, R. M.; (University of Indiana School of Medicine, Md; USA), Indianapolis; Roberts, R. C.; (Addenbrooke’s Hospital Cambridge, Md; UK), Cambridge; Rojas-Marcos, I.; (Hospital Univesitario Reina Sofia, Md; Spain), Cordoba; Roodbol, J.; Md, ; candidate (Erasmus University Medical Centre, Phd; Rotterdam, ; Netherlands), The; Rudnicki, S. A.; (University of Arkansas, Md; USA), Fayetteville; Sachs, G. M.; (University of Rhode Island, Md; USA), Providence; Schenone, A.; Md, ; Department of Neurosciences, PhD (1.; Ophthalmology, Rehabilitation; and Maternal and Infantile Sciences (DINOGMI), Genetics; of Genova, University; Genova, ; IRCCS Policlinico San Martino, Italy 2.; Italy), Genova; Sheikh, K.; Md, ; (The University of Texas Health Science Center at Houston, Phd; USA), Houston; Twydell, P.; (Spectrum Health System, Do; Rapids, Grand; USA), ; Van Damme, P.; Md, ; (University Hospital Leuven, Phd; Belgium), Leuven; Varrato, J. D.; (Lehigh Valley Health Network, Do; USA), Allentown; Visser, L. H.; Md, ; (Elisabeth-TweeSteden Hospital, Phd; and Waalwijk, Tilburg; Netherlands), The; Willison, H. J.; Md, ; (University of Glasgow, Phd; UK), Glasgow; van Woerkom (Erasmus MC, M.; Rotterdam, ; Netherlands), The; Zhou, L.; Md, ; (Icahn School, Phd. - In: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. - ISSN 0022-3050. - (2021), pp. 1080-1088. [10.1136/jnnp-2020-325815]
Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome. An international observational study
Verboon C.;Harbo T.;Cornblath D. R.;Hughes R. A. C.;Van Doorn P. A.;Lunn M. P.;Gorson K. C.;Barroso F.;Kuwabara S.;Galassi G.;Lehmann H. C.;Kusunoki S.;Reisin R. C.;Binda D.;Cavaletti G.;Jacobs B. C. H. Andersen
;MD;PhD (Aarhus University Hospital;Aarhus Denmark);S. Attarian;MD;PhD (CHU Timone;Marseille France);U. A. Badrising;MD;PhD (Leiden University Medical Centre;Leiden;The Netherlands);K. Bateman;MD;PhD (Groote Schuur Hospital;Cape Town;South-Africa);L. Benedetti;MD;PhD (Ospedale Sant’ Andrea La Spezia;La Spezia;Italy);B. van den Berg;MD (Franciscus Gasthuis;Rotterdam;The Netherlands);P. Van den Bergh;MD;PhD (University Clinic St. Luc;Leuven Belgium);T. E. Bertorini;MD (The University of Tennessee Health Science Center (UTHSC);Memphis USA);R. Bhavaraju-Sanka;MD (University Hospital/ University of Texas Health Science Center;San Antonio Texas;USA);M. Bianco (Milan University;Humanitas Clinicala and Research Institute Milan;Italy);C. Briani;MD (University of Padova;Padova Italy);J. Bürmann;MD (Universitätsklinikum des Saarlandes;Homburg Germany);C. Casasnovas;MD;PhD (Bellvitge University Hospital - IDIBELL Neurometabolic Diseases Group. CIBERER;Barcelona Spain);C. C. Chao;MD;PhD (National Taiwan University Hospital;Taipei Taiwan);G. Chavada;MD;PhD (Glasgow University;Glasgow UK);K. G. Claeys;MD;PhD (1. University Hospitals Leuven;Leuven Belgium;2. KU Leuven;Leuven Belgium);J. S. Cosgrove;MD (Leeds General Infirmary;Leeds UK);M. C. Dalakas;MD (1. Thomas Jefferson University;Philadelphia USA;2. National and Kapodistrian University of Athens;Athens Greece);A. Davidson;MD (University of Glasgow;Glasgow UK);G. W. van Dijk;MD (Canisius Wilhelmina Hospital;Nijmegen;The Netherlands);E. Dardiotis;MD (University of Thessaly;Hospital of Larissa;Larissa Greece);M. Derejko;MD (Odense University Hospital;Odense Denmark);M. M. Dimachkie;MD (University of Kansas Medical Center;Kansas City;USA);C. Dornonville de la Cour;MD (National Hospital Copenhagen;Copenhagen Denmark);A. Echaniz-Laguna;MD (Bicêtre University Hospital;Paris France);F. Eftimov;MD;PhD (Amsterdam University Medical Centre;Amsterdam;The Netherlands);C. G. Faber;MD;PhD (Maastricht University Medical Centre;Maastricht;The Netherlands);R. Fazio;MD (Scientific Institute San Raffaele;Milan Italy);J. Fehmi (University of Oxford E. A. Fulgenzi;MD (Hospital Cesar Milstein Buenos Aires;Buenos Aires;Argentina);T. García-Sobrino;MD (Hospital Clínico de Santiago;Santiago de Compostela (A Coruña);Spain);C. J. Gijsbers;MD (Vlietland Hospital;Schiedam;The Netherlands);V. Granit;MD (Montefiore Medical;Center;New York;USA);S. Grisanti;MD (Ospedale Sant’ Andrea La Spezia;La Spezia;Italy);G. Gutiérrez-Gutiérrez;MD (Hospital Universitario Infanta Sofia;San Sebastian;Spain);J. V. Holbech;MD;PhD (Odense University Hospital;Odense Denmark);J. K. L. Holt;PhD;FRCP (The Walton Centre;Liverpool UK);C. Homedes;MD (Bellvitge University Hospital - IDIBELL Neurometabolic Diseases Group. CIBERER;Barcelona Spain);B. Islam;MD;PhD (International Centre for Diarrhoeal Disease Research;Bangladesh (icddr;b) Dhaka;Bangladesh);Z. Islam;MD;PhD (International Centre for Diarrhoeal Disease Research;Bangladesh (icddr;b) Dhaka;Bangladesh);I. Jahan;PhD candidate (International Centre for Diarrhoeal Disease Research;Bangladesh (icddr;b) Dhaka;Bangladesh);I. Jericó Pascual;MD;PhD (Complejo Hospitalario de Navarra;Pamplona Spain);S. Karafiath;MD (University of Utah School of Medicine;Salt Lake City;USA);H. Kerkhoff;MD;PhD (Albert Schweitzer Hospital;Dordrecht;The Netherlands);K. Kimpinski;MD (University Hospital;LHSC London-Ontario;Canada);A. Kohler;MD (Instituto de Investigaciones Neurológicas Raúl Carrea;FLENI;Buenos Aires;Argentina);N. Kolb;MD (University of Vermont;Burlington VT;USA);K. Kuitwaard;MD;PhD (1. Albert Schweitzer Hospital;Dordrecht;2. Erasmus MC;Rotterdam;The Netherlands);M. Kuwahara;MD;PhD (Kindai University;Osaka Japan);S. S. Ladha;MD (Barrow Neurology Clinics;Phoenix Arizona;USA);E. Lee Pan;MBChB (Groote Schuur Hospital;Cape Town;South-Africa);G. A. Marfia;MD (Neurological Clinic;Policlinico Tor Vergata;Rome Italy);A. Magot;MD (Reference Centre for NMD;Nantes University Hospital;France);C. Márquez Infante;MD (Hospital Universitario Virgen del Rocio;Seville Spain);L. Martín-Aguilar;MD (Hospital de la Santa Creu i Sant Pau;Universitat Autònoma de Barcelona;Barcelona Spain);E. Martinez Hernandez;MD (Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS);Hospital Clinic;Barcelona Spain);G. Mataluni;MD;PhD (Neurological Clinic;Policlinico Tor Vergata;Rome Italy);G. Meekins;MD (University of Minnesota;USA);J. A. L. Miller;MD;PhD (Royal Victoria Infirmary;Newcastle UK);M. S. Monges;MD (Hospital de Pediatría J. P. Garrahan;Buenos Aires;Argentina);E. Nobile Orazio;MD;PhD (Milan University;Humanitas Clinicala and Research Institute Milan;Italy);A. Pardal;MD (Hospital Britanico;Buenos Aires;Argentina);J. Pardo Fernandez (Hospital Clínico de Santiago;Santiago de Compostela (A Coruña);Spain);Y. Péréon;MD;PhD (Reference Centre for NMD;Nantes University Hospital;France);M. Pulley;MD (University of Florida;Jacksonville USA);L. Querol Gutierrez;MD;PhD (Hospital de la Santa Creu i Sant Pau;Universitat Autònoma de Barcelona;Barcelona Spain);S. W. Reddel;MD;PhD (Concord Repatriation General Hospital;Sydney Australia);T. van der Ree;MD (Westfriesgasthuis;Hoorn;The Netherlands);S. Rinaldi;MBChB;PhD (University of Oxford J. P. A. Samijn;MD (Maasstad Hospital;Rotterdam;The Netherlands);M. Samukawa;MD;PhD (Kindai University;Osaka Japan);L. Santoro;MD;PhD (University Federico II;Napels Italy);A. Savransky;MD;PhD (Hospital de Pediatría J. P. Garrahan;Buenos Aires;Argentina);L. Schwindling;MD (Universitätsklinikum des Saarlandes;Homburg Germany);M. J. Sedano Tous;MD (Hospital Universitario Marques de Valdecilla;Santander Cantabria;Spain);Y. Sekiguchi;MD;PhD (Chiba University;Chiba Japan);N. Shahrizaila;MD (Neurology Unit;Department of Medicine;Faculty of Medicine;University of Malaya;Malaya);N. J. Silvestri;MD (Buffalo Jacobs School of Medicine S. Sindrup;MD;PhD (Odense University Hospital;Odense Denmark);C. L. Sommer;MD (Universitätsklinikum Würzburg;Würzburg Germany);A. Spyropoulos (Royal Victoria Infirmary;Newcastle UK);B. Stein;MD (St. Joseph’s Regional Medical Center;Paterson USA);C. Y. Tan;MRCP (Neurology Unit;Department of Medicine;Faculty of Medicine;University of Malaya;Malaya);H. Tankisi;MD;PhD (Aarhus University Hospital;Aarhus Denmark);F. Vermeij;MD (Franciscus Gasthuis;Rotterdam;The Netherlands);M. V. Vytopil;MD;PhD (Tufts University School of Medicine Lahey Hospital P. W. Wirtz;MD;PhD (HagaZiekenhuis;The Hague;The Netherlands);W. Waheed;MD (University of Vermont Medical Center;Burlington;USA). Other collaborators were:J. M. Addington;MD (University of Virginia;Charlottesville USA);S. Ajroud-Driss;MD (Northwestern University Feinberg;Chicago USA);G. Antonini;MD (Mental Health and Sensory Organs (NESMOS);Sapienza University;Sant’Andrea Hospital;Rome Italy);I. R. Bella;MD (University of Mass Medical School;Worcester USA);T. H. Brannagan;MD (Columbia University;New York City;USA);C. Bunschoten;MD;PhD candidate (Erasmus University Medical Centre;Rotterdam;The Netherlands);M. Busby;MD (Leeds General Infirmary;Bradford UK);S. Butterworth;MD (Pinderfields Hospital;Wakefield UK);M. E. Conti;MD (University Hospital Clinicas;Buenos Aires;Argentina);S. Chen;MD;PhD (Rutgers;Robert Wood Johnson University Hospital;New Brunswick;USA);A. Doets;MD;PhD candidate (Erasmus University Medical Centre;Rotterdam;the Netherlands);T. E. Feasby;MD (University of Calgary;Calgary Canada);C. Fokke;MD (Gelre Hospital;Zutphen and Apeldoorn;The Netherlands);T. Fujioka;MD (Toho University Medical Center;Tokyo Japan);M. P. J. Garssen;MD;PhD (Jeroen Bosch Hospital;’s Hertogenbosch;The Netherlands);J. M. Gilchrist;MD (Soulthern Illinois University School of Medicine;Springfield USA);J. Gilhuis;MD;PhD (Reinier de Graaf Gasthuis;Delft;The Netherlands);J. M. Goldstein;MD (Yale University School of Medicine;New Haven;USA);N. A. Goyal;MD (University of California;Irvine USA);R. D. M. Hadden;MD;PhD (King’s College Hospital;London UK);S. T. Hsieh;MD;PhD (National Taiwan University Hospital;Taipei Taiwan);M. Htut;MD (St. George’s Hospital;London UK);I. Illa;MD;PhD (Hospital de la Santa Creu i Sant Pau;Universitat Autònoma de Barcelona;Barcelona Spain);K. Jellema;MD;PhD (Haaglanden Medisch Centrum;The Hague;The Netherlands);K. Kaida;MD;PhD (National Defense Medical College;Saitama Japan);H. D. Katzberg;MD (University of Toronto;Toronto Canada);L. Kiers;MD (University of Melbourne;Royal Melbourne Hospital;Parkville Australia);N. Kokubun;MD (Dokkyo Medical University;Tochigi Japan);R. van Koningsveld;MD;PhD (Elkerliek Hospital;Helmond and Deurne;The Netherlands);A. J. van der Kooi;MD;PhD (Amsterdam University Medical Centre;Amsterdam;The Netherlands);J. Y. Kwan;MD (University of Maryland School of Medicine;Baltimore USA);L. Landschoff Lassen;MD (Glostrup Hospital;Glostrup Denmark);V. Lawson;MD (Wexner Medical Center at The Ohio State University;Columbus USA);S. E. Leonhard;MD;PhD candidate (Erasmus University Medical Centre;Rotterdam;the Netherlands);M. Mandarakas;MD;PhD (Erasmus University Medical Centre;Rotterdam;the Netherlands);H. Manji;MD;FRCP (Ipswich Hospital;Ipswich UK);M. G. Mattiazzi;MD (Hospital Militar Central;Buenos Aires;Argentina);C. J. McDermott;MD (Royal Hallamshire Hospital;NIHR Clinical;Sheffield UK);Q. D. Mohammad;MD;PhD (National Institute of Neurosciences and Hospital;Dhaka Bangladesh);G. Morís de la Tassa;MD (Hospital UniversitarioCentral de Asturias;Asturias Spain);C. Nascimbene;MD;PhD (Luigi Sacco Hospital;Milan Italy);E. H. Niks;MD;PhD (Leiden University Medical Centre;Leiden;The Netherlands);R. J. Nowak;MD (Yale University School of Medicine;New Haven;USA);M. Osei-Bonsu;MD;PhD (James Cook University Hospital;Middlesbrough UK);R. M. Pascuzzi;MD (University of Indiana School of Medicine;Indianapolis USA);R. C. Roberts;MD (Addenbrooke’s Hospital Cambridge;Cambridge UK);I. Rojas-Marcos;MD (Hospital Univesitario Reina Sofia;Cordoba Spain);J. Roodbol;MD;PhD candidate (Erasmus University Medical Centre;Rotterdam;the Netherlands);S. A. Rudnicki;MD (University of Arkansas;Fayetteville USA);G. M. Sachs;MD (University of Rhode Island;Providence USA);A. Schenone;MD;PhD (1. Department of Neurosciences;Rehabilitation Ophthalmology;Genetics and Maternal and Infantile Sciences (DINOGMI);University of Genova;Genova;Italy 2. IRCCS Policlinico San Martino;Genova Italy);K. Sheikh;MD;PhD (The University of Texas Health Science Center at Houston;Houston USA);P. Twydell;DO (Spectrum Health System;Grand Rapids;USA);P. Van Damme;MD;PhD (University Hospital Leuven;Leuven Belgium);J. D. Varrato;DO (Lehigh Valley Health Network;Allentown USA);L. H. Visser;MD;PhD (Elisabeth-TweeSteden Hospital;Tilburg and Waalwijk;The Netherlands);H. J. Willison;MD;PhD (University of Glasgow;Glasgow UK);M. van Woerkom (Erasmus MC;Rotterdam;the Netherlands);L. Zhou;MD;PhD (Icahn School
2021
Abstract
Objective: To compare the disease course in patients with mild Guillain-Barré syndrome (GBS) who were treated with intravenous immunoglobulin (IVIg) or supportive care only. Methods: We selected patients from the prospective observational International GBS Outcome Study (IGOS) who were able to walk independently at study entry (mild GBS), treated with one IVIg course or supportive care. The primary endpoint was the GBS disability score four weeks after study entry, assessed by multivariable ordinal regression analysis. Results: Of 188 eligible patients, 148 (79%) were treated with IVIg and 40 (21%) with supportive care. The IVIg group was more disabled at baseline. IVIg treatment was not associated with lower GBS disability scores at 4 weeks (adjusted OR (aOR) 1.62, 95% CI 0.63 to 4.13). Nearly all secondary endpoints showed no benefit from IVIg, although the time to regain full muscle strength was shorter (28 vs 56 days, p=0.03) and reported pain at 26 weeks was lower (n=26/121, 22% vs n=12/30, 40%, p=0.04) in the IVIg treated patients. In the subanalysis with persistent mild GBS in the first 2 weeks, the aOR for a lower GBS disability score at 4 weeks was 2.32 (95% CI 0.76 to 7.13). At 1 year, 40% of all patients had residual symptoms. Conclusion: In patients with mild GBS, one course of IVIg did not improve the overall disease course. The certainty of this conclusion is limited by confounding factors, selection bias and wide confidence limits. Residual symptoms were often present after one year, indicating the need for better treatments in mild GBS.
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.08 MB
Formato
Adobe PDF
1.08 MB
Adobe PDF
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1565123
Citazioni
4
19
16
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
